rtmark
LearnBonds.com

Monday View: Three health stocks battling coronavirus

Pharmaceutical companies across the globe are rushing to develop a treatment or vaccine to counter the fast-spreading coronavirus that has cause economies around the world to stall. Along with medical researchers, not-for-profit organizations and public health authorities, several medical companies are developing innovative solutions to fight the deadly virus.

According to analysts, these new technologies can be a turning point in the war against the new threat, and could even help drive the stock market’s recovery. And in the case of Abbott Labs, Johnson & Johnson and Gilead Sciences – the efforts of these companies towards curbing the health crisis that has gripped the globe have put their stocks on the forefront of investors’ minds in recent weeks.

US-based Abbott is a key firm fighting against the novel coronavirus disease after it received emergency use authorization from the Food and Drug Administration for a new test that can provide results in as little as five minutes.

With sales already soaring for one of Abbott’s most important growth drivers, the company generated revenue of close to $2bn, up 70% year-on-year. Abbott Labs, based in Illinois, also continues to enjoy strong momentum for several other products in its lineup with its shares of Abbott Laboratories registering a 4.6% in one week.

Monday View: Three health...

Gilead Sciences is another stock that is benefiting from the company’s active role in developing an effective treatment for the new coronavirus. Its latest drug is in late-stage clinical studies but demand is already so high that the company had to stop accepting new requests for Remdesivir with a few exceptions. This caused the company’s stock to move -1.54% from the previous trading session, closing at $74.76.

Monday View: Three health...

Johnson & Johnson will start testing of vaccines in humans as early as September, which means doses of the first vaccine against coronavirus could be available under Emergency Use Authorization (EUA) in early 2021 if testing goes well.  After the pharmaceutical giant significantly expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA), it went on to secure a $1bn deal with the US government for vaccine’s development and clinical testing.  The news of the drugmaker’s deal caused J&J’s shares to J&J to gain 8% in Monday’s trading session.

Monday View: Three health...

Buying individual shares is always a risk, particularly when it comes to new technology and medicines, but these are a few stocks larger funds are buying.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
Users should remember that all trading carries risks and users should only invest in regulated firms. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Galina Mikova

Galina is a Hubspot-certified Technical Writer with over 10 years of experience in working with Fortune 500, private investment, banking, FOREX and niche tech companies as well as crypto and blockchain startups. She has a solid background in FinTech and blockchain technology.